Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,442 across all filing types
Latest filing 2021-06-10 Capital/Financing Update
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Proposed issue of securities - IMU 7 pages 31.8KB
Capital/Financing Update Classification · 95% confidence The document is an announcement from Imugene Limited regarding a proposed issue of securities, specifically a placement or other type of issue. It details the number of securities to be issued, the issue price, the class of securities, and other related information. The document is structured as an announcement to the ASX (Australian Securities Exchange) and includes compliance with listing rules. There is no financial performance data, management discussion, or audit information. The content is focused on capital raising activities and changes in the company's capital structure. Therefore, this document fits the category of Capital/Financing Update (CAP). The document length is 8800 characters, which is consistent with a detailed announcement rather than a brief notice or a full report.
2021-06-10 English
Imugene Appoints Dr Monil Shah as Chief Business Officer 2 pages 151.3KB
Board/Management Information Classification · 100% confidence The document is an ASX announcement dated 10 June 2021 about the appointment of Dr Monil Shah as Chief Business Officer at Imugene Limited. It focuses on management changes and biographical details of the new executive. There is no financial data, no report or presentation attached, and no mention of voting results or regulatory filings. The content clearly fits the category of announcing changes in senior management. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is 4658 characters, which is consistent with a typical management announcement rather than a full report or presentation.
2021-06-09 English
Proposed issue of Securities - IMU 5 pages 28.1KB
Capital/Financing Update Classification · 100% confidence The document is an announcement regarding a proposed issue of securities by Imugene Limited. It details the number of securities to be issued, the issue price, the class of securities, and compliance with ASX listing rules. There is no financial performance data, management discussion, or audit information. The document is focused on capital raising activities and changes in the company's capital structure. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is sufficient and contains substantive details about the proposed issue, not just a brief notice or link to a report, so it is not a Report Publication Announcement or Regulatory Filing.
2021-06-03 English
Appendix 2A 15 pages 394.4KB
Regulatory Filings Classification · 100% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX (Australian Securities Exchange). It includes detailed information about the entity, the securities to be quoted, and references to previous announcements such as Appendix 3B. The document is a regulatory form used to notify the exchange about new securities being issued and their quotation. It is not a financial report, earnings release, or management discussion. It is also not a report publication announcement since it contains substantive information about the securities issuance. This type of document fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement related to compliance with listing rules and securities quotation requirements.
2021-06-03 English
Managing Director and CEO increases shareholding in Imugene 2 pages 164.9KB
Director's Dealing Classification · 95% confidence The document is an ASX announcement regarding the Managing Director and CEO exercising options and increasing shareholding. It mentions forthcoming filings such as Appendix 3B, 2A, and 3Y related to director's interest changes. The content focuses on a director's personal share transactions and option exercises, which aligns with insider trading or director dealings. The document length is short (2966 characters) and does not contain financial statements or detailed financial results. Therefore, it is not an annual report, earnings release, or other financial report. The best fitting category is Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives.
2021-05-27 English
Proposed issue of Securities - IMU 6 pages 29.9KB
Capital/Financing Update Classification · 95% confidence The document is an announcement from Imugene Limited regarding a proposed issue of securities, specifically a placement or other type of issue of ordinary fully paid shares. It includes details such as the number of securities to be issued, issue prices, dates, and compliance with ASX listing rules. There are no financial statements, management discussion, or detailed financial analysis present. The document is a formal notification about capital raising activities rather than a full financial report or earnings release. Therefore, it fits the category of Capital/Financing Update (CAP). The document length (6726 characters) supports it being a detailed announcement rather than a brief notice or a full report.
2021-05-27 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.